Markolf Hanefeld
Overview
Explore the profile of Markolf Hanefeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
5241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pistrosch F, Matschke J, Schipp D, Schipp B, Henkel E, Weigmann I, et al.
Diabetologia
. 2021 Sep;
64(12):2701-2712.
PMID: 34495376
Aims/hypothesis: Individuals with type 2 diabetes mellitus and subclinical inflammation have stimulated coagulation, activated platelets and endothelial dysfunction. Recent studies with the direct factor Xa inhibitor rivaroxaban in combination with...
2.
Bajaj H, Gerstein H, Rao-Melacini P, Basile J, Colhoun H, Conget I, et al.
Lancet Diabetes Endocrinol
. 2021 Jun;
9(8):484-490.
PMID: 34153269
Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 receptor agonists on erectile dysfunction is unknown. We aimed to assess the incidence, prevalence, and...
3.
Hanefeld M, Zitzmann M, Nieschlag E
Dtsch Med Wochenschr
. 2021 May;
146(15):1016.
PMID: 34010959
No abstract available.
4.
Drzewoski J, Hanefeld M
Pharmaceuticals (Basel)
. 2021 Feb;
14(2).
PMID: 33562458
Metformin, one of the oldest oral antidiabetic agents and still recommended by almost all current guidelines as the first-line treatment for type 2 diabetes mellitus (T2DM), has become the medication...
5.
Tschiderer L, Seekircher L, Klingenschmid G, Izzo R, Baldassarre D, Iglseder B, et al.
Gerontology
. 2020 Jul;
66(5):447-459.
PMID: 32610336
Atherosclerosis - the pathophysiological mechanism shared by most cardiovascular diseases - can be directly or indirectly assessed by a variety of clinical tests including measurement of carotid intima-media thickness, carotid...
6.
Hanefeld M, Fleischmann H, Siegmund T, Seufert J
Diabetes Ther
. 2020 Jun;
11(8):1645-1666.
PMID: 32564335
Type 2 diabetes is characterised by chronic hyperglycaemia and variable degrees of insulin deficiency and resistance. Hyperglycaemia and elevated fatty acids exert harmful effects on β-cell function, regeneration and apoptosis...
7.
Haider K, Haider A, Saad F, Doros G, Hanefeld M, Dhindsa S, et al.
Diabetes Obes Metab
. 2020 Jun;
22(11):2055-2068.
PMID: 32558149
Aims: To investigate whether testosterone therapy (TTh) in men with hypogonadism and type 2 diabetes mellitus (T2DM) improves glycaemic control and insulin sensitivity, and results in remission of T2DM. Material...
8.
Gerstein H, Hart R, Colhoun H, Diaz R, Lakshmanan M, Botros F, et al.
Lancet Diabetes Endocrinol
. 2020 Jan;
8(2):106-114.
PMID: 31924562
Background: Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with...
9.
Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P, et al.
Lancet
. 2019 Jun;
394(10193):121-130.
PMID: 31189511
Background: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A (HbA) concentrations. We assessed...
10.
Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P, et al.
Lancet
. 2019 Jun;
394(10193):131-138.
PMID: 31189509
Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor...